127 related articles for article (PubMed ID: 38703119)
41. Targeting CYP51 for drug design by the contributions of molecular modeling.
Rabelo VW; Santos TF; Terra L; Santana MV; Castro HC; Rodrigues CR; Abreu PA
Fundam Clin Pharmacol; 2017 Feb; 31(1):37-53. PubMed ID: 27487199
[TBL] [Abstract][Full Text] [Related]
42. Design, synthesis and evaluation of benzoheterocycle analogues as potent antifungal agents targeting CYP51.
Zhao S; Wei P; Wu M; Zhang X; Zhao L; Jiang X; Hao C; Su X; Zhao D; Cheng M
Bioorg Med Chem; 2018 Jul; 26(12):3242-3253. PubMed ID: 29748145
[TBL] [Abstract][Full Text] [Related]
43. Imidazolylchromanones containing alkyl side chain as lanosterol 14α-demethylase inhibitors: synthesis, antifungal activity and docking study.
Emami S; Banipoulad T; Irannejad H; Foroumadi A; Falahati M; Ashrafi-Khozani M; Sharifynia S
J Enzyme Inhib Med Chem; 2014 Apr; 29(2):263-71. PubMed ID: 23488742
[TBL] [Abstract][Full Text] [Related]
44. Lanosterol 14α-demethylase (CYP51)/histone deacetylase (HDAC) dual inhibitors for treatment of Candida tropicalis and Cryptococcus neoformans infections.
Zhu T; Chen X; Li C; Tu J; Liu N; Xu D; Sheng C
Eur J Med Chem; 2021 Oct; 221():113524. PubMed ID: 33992927
[TBL] [Abstract][Full Text] [Related]
45. Pyridylethanol(phenylethyl)amines are non-azole, highly selective Candida albicans sterol 14α-demethylase inhibitors.
Ogris I; Zelenko U; Sosič I; Gobec M; Skubic C; Ivanov M; Soković M; Kocjan D; Rozman D; Golič Grdadolnik S
Bioorg Chem; 2021 Jan; 106():104472. PubMed ID: 33261849
[TBL] [Abstract][Full Text] [Related]
46. In silico prediction of Antifungal compounds from Natural sources towards Lanosterol 14-alpha demethylase (CYP51) using Molecular docking and Molecular dynamic simulation.
Sama-Ae I; Pattaranggoon NC; Tedasen A
J Mol Graph Model; 2023 Jun; 121():108435. PubMed ID: 36848730
[TBL] [Abstract][Full Text] [Related]
47. In silico and in vitro screening to identify structurally diverse non-azole CYP51 inhibitors as potent antifungal agent.
Singh A; Paliwal SK; Sharma M; Mittal A; Sharma S; Sharma JP
J Mol Graph Model; 2016 Jan; 63():1-7. PubMed ID: 26579619
[TBL] [Abstract][Full Text] [Related]
48. Design, Synthesis, and Fungicidal Activities of Novel 5-Methyl-1H-1,2,3- trizole-4-carboxyl Amide Analogues.
Wang ZJ; Yang HH; Tian L; Zhao WG
Med Chem; 2016; 12(3):290-5. PubMed ID: 26558376
[TBL] [Abstract][Full Text] [Related]
49. The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme.
Warrilow AG; Hull CM; Parker JE; Garvey EP; Hoekstra WJ; Moore WR; Schotzinger RJ; Kelly DE; Kelly SL
Antimicrob Agents Chemother; 2014 Dec; 58(12):7121-7. PubMed ID: 25224009
[TBL] [Abstract][Full Text] [Related]
50. Design, synthesis, and in vitro antifungal activity of 1-[(4-substituted-benzyl)methylamino]-2-(2,4-difluorophenyl)-3-(1H-1,2,4-triazol-1-yl)propan-2-ols.
Guillon R; Pagniez F; Giraud F; Crépin D; Picot C; Le Borgne M; Morio F; Duflos M; Logé C; Le Pape P
ChemMedChem; 2011 May; 6(5):816-25. PubMed ID: 21370476
[TBL] [Abstract][Full Text] [Related]
51. Shape and pharmacophore-based virtual screening to identify potential cytochrome P450 sterol 14α-demethylase inhibitors.
Reddy KK; Singh SK; Tripathi SK; Selvaraj C; Suryanarayanan V
J Recept Signal Transduct Res; 2013 Aug; 33(4):234-43. PubMed ID: 23638723
[TBL] [Abstract][Full Text] [Related]
52. Design, synthesis and antifungal activities of novel 1,2,4-triazole derivatives.
Xu J; Cao Y; Zhang J; Yu S; Zou Y; Chai X; Wu Q; Zhang D; Jiang Y; Sun Q
Eur J Med Chem; 2011 Jul; 46(7):3142-8. PubMed ID: 21420761
[TBL] [Abstract][Full Text] [Related]
53. Homology model, molecular dynamics simulation and novel pyrazole analogs design of Candida albicans CYP450 lanosterol 14 α-demethylase, a target enzyme for antifungal therapy.
Jacob K S; Ganguly S; Kumar P; Poddar R; Kumar A
J Biomol Struct Dyn; 2017 May; 35(7):1446-1463. PubMed ID: 27142238
[TBL] [Abstract][Full Text] [Related]
54.
Singh G
Curr Drug Discov Technol; 2022; 19(6):e150622206033. PubMed ID: 35708080
[TBL] [Abstract][Full Text] [Related]
55. Synthesis and mode of action studies of novel {2-(3-R-1H-1,2,4-triazol-5-yl)phenyl}amines to combat pathogenic fungi.
Antypenko L; Sadykova Z; Shabelnyk K; Meyer F; Kovalenko S; Meyer V; Garbe LA; Steffens K
Arch Pharm (Weinheim); 2019 Oct; 352(10):e1900092. PubMed ID: 31463959
[TBL] [Abstract][Full Text] [Related]
56. Structural basis for rational design of inhibitors targeting Trypanosoma cruzi sterol 14α-demethylase: two regions of the enzyme molecule potentiate its inhibition.
Friggeri L; Hargrove TY; Rachakonda G; Williams AD; Wawrzak Z; Di Santo R; De Vita D; Waterman MR; Tortorella S; Villalta F; Lepesheva GI
J Med Chem; 2014 Aug; 57(15):6704-17. PubMed ID: 25033013
[TBL] [Abstract][Full Text] [Related]
57. Synthesis, antifungal activities and qualitative structure activity relationship of carabrone hydrazone derivatives as potential antifungal agents.
Wang H; Ren SX; He ZY; Wang DL; Yan XN; Feng JT; Zhang X
Int J Mol Sci; 2014 Mar; 15(3):4257-72. PubMed ID: 24619221
[TBL] [Abstract][Full Text] [Related]
58. Design, synthesis, and structure-activity relationship studies of novel triazole agents with strong antifungal activity against Aspergillus fumigatus.
Ding Z; Ni T; Xie F; Hao Y; Yu S; Chai X; Jin Y; Wang T; Jiang Y; Zhang D
Bioorg Med Chem Lett; 2020 Feb; 30(4):126951. PubMed ID: 31926784
[TBL] [Abstract][Full Text] [Related]
59. Structural insight into the unique binding properties of pyridylethanol(phenylethyl)amine inhibitor in human CYP51.
Zelenko U; Hodošček M; Rozman D; Golič Grdadolnik S
J Chem Inf Model; 2014 Dec; 54(12):3384-95. PubMed ID: 25419870
[TBL] [Abstract][Full Text] [Related]
60. The binding mechanism between azoles and FgCYP51B, sterol 14α-demethylase of Fusarium graminearum.
Qian H; Duan M; Sun X; Chi M; Zhao Y; Liang W; Du J; Huang J; Li B
Pest Manag Sci; 2018 Jan; 74(1):126-134. PubMed ID: 28719051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
